http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-PA02000969-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de50a949527f170e64b086b37edc36af
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16051
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
filingDate 2000-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_884a464fecea7228fa0365cbcbf3adf6
publicationDate 2004-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MX-PA02000969-A
titleOfInvention VACCINE OF HUMAN IMMUNE-DEFICIENCY VIRUS ATTENTION CONTROLLED IN CONDITIONAL FORM.
abstract The present invention provides an attenuated HIV vaccine comprising a modified HIV virus so that it replicates only in the presence of at least one tetracycline analog. Additionally, the present invention provides a method for immunization of humans against HIV which comprises administering to a human a vaccine that includes a modified HIV virus so that it replicates only in the presence of at least one tetracycline analog. Simultaneously, at least one tetracycline analog is administered for a period sufficient to allow replication of the modified HIV virus in vivo in sufficient quantity to produce immunity. Preferably, the tetracycline analog is doxycycline. A competent replication HIV-DoxT virus genome is produced, which can be controlled by the presence or absence of doxycycline by preparing a promoter, TetopTCAT; producing a provirus, pVIH-DoxT, using the TetopCAT promoter, and transfecting pVIH-DoxT in cell lines in the presence of doxycycline. A competent replication HIV-DoxSp virus genome is produced, which can be controlled by the presence or absence of doxycycline by preparing a promoter, TetopSpCAT; producing a provirus, pVIH-DoxSp, using the TetopCAT promoter, and transfecting pVIH-DoxSp in cell lines in the presence of doxycycline. HIV vaccines are prepared using the genomes of HIV-DoxT and HIV-DoxSp viruses. These viruses and doxycycline are administered to human hosts. Doxycycline is administered for a sufficient time to accumulate immunity and then drug administration is stopped so that doxycycline-dependent viruses no longer replicate.
priorityDate 1999-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454031468
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54684461

Total number of triples: 36.